The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor (1996)

Peer-Reviewed Study · Didier A, Loor F · September 1996

Didier A et al., 1996-09: Cell study showing ivermectin restores drug retention in multidrug-resistant mouse and human leukemia cell lines, acting as a P-glycoprotein substrate and inhibitor – the basis of the MDR-reversal claim.

Therefore, like CsA or FK-506, ivermectin may also be a substrate and an inhibitor of Pgp.

Didier A et al., 1996-09: Cell study showing ivermectin restores drug retention in multidrug-resistant mouse and human leukemia cell lines, acting as a P-glycoprotein substrate and inhibitor – the basis of the MDR-reversal claim. C3 multidrug resistance / P-glycoprotein mechanism. Study type: cell lines (murine monocytic leukemia MDR-P388, human lymphocytic leukemia MDR-CEM) plus prior in vivo mouse tolerability observations. Country: France (Immunology Laboratory, Strasbourg 1 University, Illkirch). Concentration: not stated in the abstract captured; effect compared with SDZ PSC 833. Route/schedule: in vitro. Funder: not stated in the PubMed record. Declared conflicts: none captured. Comparator: parental drug-sensitive cells and the P-gp inhibitor SDZ PSC 833. Relevance to safety: the same P-gp interaction is the mechanism behind ivermectin neurotoxicity when the blood-brain barrier transporter is blocked or absent (see C9). Study type: lab.